<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04123613</url>
  </required_header>
  <id_info>
    <org_study_id>DM199-2019-001</org_study_id>
    <nct_id>NCT04123613</nct_id>
  </id_info>
  <brief_title>Multiple Doses of DM199 in Patients With Chronic Kidney Disease</brief_title>
  <official_title>A Multi-Center Open-label Investigation to Assess the Safety and Efficacy of Multiple Doses of DM199 in Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DiaMedica Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DiaMedica Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, Phase II, multi-center study evaluating multiple doses of DM199 in&#xD;
      participants with chronic kidney disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, Phase II, multi-center study evaluating DM199 in approximately 90&#xD;
      Participants in three cohorts.&#xD;
&#xD;
      Cohort I: African Americans with CKD (Stage II or III), hypertension and non-diabetic Cohort&#xD;
      II: Participants with IgA nephropathy diagnosis and CKD (Stage II or III) Cohort III:&#xD;
      Diabetes Mellitus (Type II) with CKD (Stage II or III) and hypertension&#xD;
&#xD;
      Participants in each cohort will be enrolled in a parallel assignment to one of two doses:&#xD;
&#xD;
      Dose 1: DM199 2.0 µg/kg SC 2x week for 95 days Dose 2: DM199 5.0 µg/kg SC 2x week for 95 days&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence, severity, and causality of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in renal function</measure>
    <time_frame>12 weeks</time_frame>
    <description>eGFR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in urine albumin to creatinine ratio</measure>
    <time_frame>12 weeks</time_frame>
    <description>UACR change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma measurements of DM199</measure>
    <time_frame>12 weeks</time_frame>
    <description>Maximum plasma concentration of DM199</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor necrosis factor receptor 1 (TNF R1) concentration in plasma, change from baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>TNF R1 change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (CRP) concentration in plasma, change from baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>CRP change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matrix metalloproteainase-9 (MMP-9) concentration in plasma, change from baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>MMP-9 change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular endothelial growth factor (VEGF) concentration in plasma, change from baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>VEGF change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystatin C concentration in plasma, change from baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Cystatin C change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostaglandin E2 concentration in plasma, change from baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Prostaglandin E2 change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostacyclin concentration in plasma, change from baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Prostacyclin change from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>2.0 µg/kg, multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=45 with 15 Participants from cohort 1, 15 from cohort 2, and 15 from cohort 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5.0 µg/kg, multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n=45 with 15 Participants from cohort 1, 15 from cohort 2 and 15 from cohort 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DM199</intervention_name>
    <description>A pharmaceutical formulation comprised of recombinant human tissue kallikrein-1 (rhKLK-1) that is being developed as an injectable protein drug</description>
    <arm_group_label>2.0 µg/kg, multiple dose</arm_group_label>
    <arm_group_label>5.0 µg/kg, multiple dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cohort I&#xD;
&#xD;
          -  African American&#xD;
&#xD;
          -  Hypertension as defined by the American Heart Association for Stage I hypertension&#xD;
             where systolic blood pressure (BP) ≥130 mmHg or diastolic BP ≥ 80 mmHg or on&#xD;
             medication for treatment of hypertension.&#xD;
&#xD;
        Cohort II&#xD;
&#xD;
          -  IgA nephropathy confirmed by medical history with biopsy&#xD;
&#xD;
        Cohort III&#xD;
&#xD;
          -  Diabetes Mellitus (Type 2) with hypertension where systolic blood pressure (BP) ≥130&#xD;
             mmHg or diastolic BP ≥ 80 mmHg or on medication for treatment of hypertension&#xD;
&#xD;
          -  Hemoglobin A1c ≥7% at screening&#xD;
&#xD;
        Both Cohorts&#xD;
&#xD;
          -  Participant is willing and able to provide informed consent for study participation&#xD;
&#xD;
          -  Participant male or female ≥ 18 years of age&#xD;
&#xD;
          -  Participant has CKD as defined by using CKD EPI for Stage II 60 to &lt;90 mL/min/1.73 m2&#xD;
             or Stage III 30 to &lt;60 mL/min/1.73 m2&#xD;
&#xD;
          -  UACR &gt;150 mg/g and &lt;5000 mg/g at screening&#xD;
&#xD;
          -  Participant is clinically stable with respect to underlying renal impairment as&#xD;
             assessed by the Investigator's medical evaluation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has positive drug test for drugs of abuse and/or positive alcohol breath&#xD;
             test at screening and Day 1&#xD;
&#xD;
          -  Participant has a current diagnosis and/or is taking medication or diet control for&#xD;
             diabetes (cohort I and II only)&#xD;
&#xD;
          -  Participant has an A1c &gt; 7% at screening (cohort I and II only)&#xD;
&#xD;
          -  Participant received corticosteroid therapy within last 3 months&#xD;
&#xD;
          -  Participant is unable or unwilling to comply with protocol requirements, including&#xD;
             assessments, tests, and follow-up visits&#xD;
&#xD;
          -  Participant has a history of significant allergic diathesis such as urticaria,&#xD;
             angioedema, or anaphylaxis&#xD;
&#xD;
          -  Participant has been previously diagnosed with kidney disease other than for&#xD;
             hypertension, IgA or Diabetes Mellitus (Type II)&#xD;
&#xD;
          -  Participant has hypotension as defined by systolic blood pressure ≤ 90 mmHg and&#xD;
             diastolic blood pressure ≤ 60 mmHg at screen&#xD;
&#xD;
          -  ACEi or GLP-1 medication prescribed for and taken by Participant (must not be taking&#xD;
             for 5 half-lives prior to study drug administration and for 10 days post study drug&#xD;
             administration)&#xD;
&#xD;
          -  Participant has a current malignancy or active malignancy ≤ 2 years prior to&#xD;
             enrollment except basal cell or squamous cell carcinoma of the skin or in situ&#xD;
             cervical cancer that has undergone potentially curative therapy and ≥ 6 months have&#xD;
             elapsed since the procedure&#xD;
&#xD;
          -  Participant has an active infection at the time of enrollment, and/or a history of&#xD;
             clinically significant acute bacterial, viral, or fungal systemic infections that&#xD;
             required systemic treatment with a completed therapy in the last 7 days prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Participant has known medical history of alpha 1-antitrypsin deficiency&#xD;
             (α1-antitrypsin deficiency)&#xD;
&#xD;
          -  Participant is pregnant or nursing or is planning a pregnancy during the study period&#xD;
&#xD;
          -  Participant is male or female of childbearing potential, is participating in sexual&#xD;
             activity that could lead to pregnancy and is unable or unwilling to practice medically&#xD;
             effective contraception during the study&#xD;
&#xD;
          -  Participant has received any investigational drug or device within 14 days (or 5 half&#xD;
             lives, whichever is longer) prior to study drug administration starting on Day 1&#xD;
&#xD;
          -  Participant has renal artery stenosis as determined at screen with medical history&#xD;
&#xD;
          -  Participant received a kidney transplant&#xD;
&#xD;
          -  Participant does not have adequate venous access for blood sampling&#xD;
&#xD;
          -  Participant has any other medical condition which, in the opinion of the Investigator,&#xD;
             will make participation medically unsafe or interfere with the study results&#xD;
&#xD;
          -  Participant has any other clinically significant abnormalities in laboratory test&#xD;
             results at screening that would, in the opinion of the Investigator, increase the&#xD;
             Participant's risk of participation, jeopardize complete participation in the study,&#xD;
             or compromise interpretation of study data&#xD;
&#xD;
          -  Participant has any significant arrhythmia or conduction abnormality, which in the&#xD;
             opinion of the Investigators and Medical Monitor may interfere with the safety of the&#xD;
             Participant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry Alcorn, Pharm.D.</last_name>
    <role>Study Director</role>
    <affiliation>DiaMedica Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sydney A Gilman, PHD</last_name>
    <phone>240.644.8353</phone>
    <email>sgilman@diamedica.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beth Larson-DeBruzzi, PharmD</last_name>
    <phone>763.496.5192</phone>
    <email>blarson@diamedica.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aventiv Research</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Zolondek</last_name>
    </contact>
    <investigator>
      <last_name>Kenneth Boren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amcis Research Center</name>
      <address>
        <city>Granada Hills</city>
        <state>California</state>
        <zip>91334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harvey Rosales</last_name>
    </contact>
    <investigator>
      <last_name>Anant Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IMD Clinical Trials Inc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Cruz</last_name>
    </contact>
    <investigator>
      <last_name>Victor Carabello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amicis Reserch Center</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Macias</last_name>
    </contact>
    <investigator>
      <last_name>Billy Hour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innovative Healthcare Institute</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gauri Barot</last_name>
    </contact>
    <investigator>
      <last_name>Paramjit Kalirao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elixia at Florida Kidney Physicians-SE</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blanca Molina</last_name>
    </contact>
    <investigator>
      <last_name>Zachary Yablon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pines Clinical Research-Hollywood</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Varon</last_name>
    </contact>
    <investigator>
      <last_name>Steven Zeig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elixia at Florida Kidney Physicians</name>
      <address>
        <city>Temple Terrace</city>
        <state>Florida</state>
        <zip>33637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosilis Castellanos</last_name>
    </contact>
    <investigator>
      <last_name>Pablo Ruiz-Ramon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boise Kidney &amp; Hypertension Institute</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Douthit</last_name>
    </contact>
    <investigator>
      <last_name>Arnold Silva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research by Design LLC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60643</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriana Vallejo</last_name>
    </contact>
    <investigator>
      <last_name>Paul Crawford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research, an AMR Company</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danna Perrier</last_name>
    </contact>
    <investigator>
      <last_name>Ramon Vargas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elixia At Clincal Renal Associates</name>
      <address>
        <city>Upland</city>
        <state>Pennsylvania</state>
        <zip>19013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Hawk</last_name>
    </contact>
    <investigator>
      <last_name>Nathan Okechukwu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nephrotex Research Group, LLC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisha Shelton</last_name>
    </contact>
    <investigator>
      <last_name>Sumit Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RDRI</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zena Cooper</last_name>
    </contact>
    <investigator>
      <last_name>Venkata Yalamanchili, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 8, 2019</study_first_submitted>
  <study_first_submitted_qc>October 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2019</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

